TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ) has provided an announcement.
Venus Medtech reported its annual financial results for 2024, showing a slight decline in revenue and gross profit compared to 2023. Despite the decrease in revenue and an increase in losses, the company achieved a significant improvement in its non-IFRS commercialization profit and profit margin, indicating enhanced commercialization capabilities. The results highlight ongoing challenges in managing costs and improving profitability, which are crucial for the company’s future growth and market positioning.
More about Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. is a joint stock company incorporated in China, specializing in the medical technology industry. The company focuses on developing and commercializing innovative medical devices, particularly in the field of heart valve products, to address unmet clinical needs and improve patient outcomes.
YTD Price Performance: -51.07%
Average Trading Volume: 32,583,410
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$1.21B
Learn more about 2500 stock on TipRanks’ Stock Analysis page.